Get started
AbbVie Inc.AA

AbbVie Inc.

183.26USDR
+0.72+0.39%
At close at May 23, 23:58 GMT
USD
No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

ABBV chart


Full chart

ABBV upcoming earnings


Next report date
≈
July 25
Report period
Q2 2025
EPS estimate
3.22 USD
Revenue estimate
‪14.95 B‬ USD

Key stats


Market capitalization
‪323.71 B‬ USD
Dividend yield (indicated)
3.61%
Price to earnings Ratio (TTM)
77.84
Basic EPS (TTM)
2.35 USD
Net income (FY)
‪4.24 B‬ USD
Revenue (FY)
‪56.33 B‬ USD
Shares float
‪1.76 B‬
Beta (1Y)
0.33

Employees


Employees (FY)
‪55 K‬
Change (1Y)
‪+5 K‬ +10.00%
Revenue / Employee (1Y)
‪1.02 M‬ USD
Net income / Employee (1Y)
‪77.05 K‬ USD

About AbbVie Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Robert A. Michael
Website
abbvie.com
Headquarters
North Chicago
Founded
2011
FIGI
BBG0025Y4RY4
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financials


Performance
‪−4%‬
‪0%‬
‪4%‬
‪8%‬
‪12%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−5.50 B‬‬
‪0.00‬
‪‪5.50 B‬‬
‪‪11.00 B‬‬
‪‪16.50 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Jul 25, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.90‬
‪1.80‬
‪2.70‬
‪3.60‬
Actual
Estimate

ABBV news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ABBV highest yielding bonds


A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
7.83%
Maturity date
Mar 15, 2045
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
7.77%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
7.67%
Maturity date
Oct 1, 2042
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
6.95%
Maturity date
Mar 15, 2035
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
6.57%
Maturity date
Nov 21, 2049
US287YAW9
ABBVIE 16/46
Yield to maturity
6.47%
Maturity date
May 14, 2046
4ABB
ABBVIE 15/45
Yield to maturity
6.35%
Maturity date
May 14, 2045
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
6.31%
Maturity date
Oct 1, 2042
ABBV4036937
AbbVie Inc. 4.4% 06-NOV-2042
Yield to maturity
6.30%
Maturity date
Nov 6, 2042
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
6.28%
Maturity date
Nov 14, 2048
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
6.24%
Maturity date
Jun 15, 2044

See all ABBV bonds 

Sparks


Curated watchlists where ABBV is featured.

See all sparks 

Frequently Asked Questions


The current price of ABBV is 183.26 USD — it has increased by 0.39% in the past 24 hours. Watch AbbVie Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie Inc. stocks are traded under the ticker ABBV.
ABBV stock has risen by 1.08% compared to the previous week, the month change is a 4.72% rise, over the last year AbbVie Inc. has showed a 15.24% increase.
We've gathered analysts' opinions on AbbVie Inc. future price: according to them, ABBV price has a max estimate of 251.00 USD and a min estimate of 173.00 USD. Watch ABBV chart and read a more detailed AbbVie Inc. stock forecast: see what analysts think of AbbVie Inc. and suggest that you do with its stocks.
ABBV reached its all-time high on Mar 10, 2025 with the price of 218.66 USD, and its all-time low was 32.51 USD and was reached on Dec 17, 2012. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
ABBV stock is 1.32% volatile and has beta coefficient of 0.33. Track AbbVie Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie Inc. there?
Today AbbVie Inc. has the market capitalization of ‪323.71 B‬, it has decreased by −0.05% over the last week.
Yes, you can track AbbVie Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie Inc. is going to release the next earnings report on Jul 25, 2025. Keep track of upcoming events with our Earnings Calendar.
ABBV earnings for the last quarter are 2.46 USD per share, whereas the estimation was 2.38 USD resulting in a 3.39% surprise. The estimated earnings for the next quarter are 3.22 USD per share. See more details about AbbVie Inc. earnings.
AbbVie Inc. revenue for the last quarter amounts to ‪13.34 B‬ USD, despite the estimated figure of ‪12.93 B‬ USD. In the next quarter, revenue is expected to reach ‪14.95 B‬ USD.
ABBV net income for the last quarter is ‪1.28 B‬ USD, while the quarter before that showed ‪−32.00 M‬ USD of net income which accounts for ‪4.09 K‬% change. Track more AbbVie Inc. financial stats to get the full picture.
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.64 USD. As of today, Dividend Yield (TTM)% is 3.48%. Tracking AbbVie Inc. dividends might help you take more informed decisions.
AbbVie Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 24, 2025, the company has ‪55 K‬ employees. See our rating of the largest employees — is AbbVie Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie Inc. EBITDA is ‪25.94 B‬ USD, and current EBITDA margin is 44.40%. See more stats in AbbVie Inc. financial statements.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie Inc. stock shows the buy signal. See more of AbbVie Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.